LS

Lovely Sinharay

Active Director Director DIN 10509734
DIN 10509734 First appointment Feb 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Feb 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Lovely Sinharay

Data last updated:

Lovely Sinharay is a Director at Pundarik Pharma Private Limited (since 2024) and Director at Medikrish Biotech Private Limited (since 2024).

DIN 10509734
Primary Designation Director
First Appointment 15 Feb 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Pundarik Pharma Private Limited U46497WB2024PTC270707
Director17 May 20242024Active
Medikrish Biotech Private Limited U46497WB2024PTC268430
Director15 Feb 20242024Active

Board colleagues of Lovely Sinharay

Directorship timeline

Open interactive timeline →
Pundarik Pharma Private Limited
Medikrish Biotech Private Limited
Premium access

Shareholding and investment profile for Lovely Sinharay

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lovely Sinharay

Lovely Sinharay currently holds 2 directorships: Pundarik Pharma Private Limited (Director, since 17 May 2024); Medikrish Biotech Private Limited (Director, since 15 Feb 2024).

Lovely Sinharay was first appointed on 15 Feb 2024 as Director at Medikrish Biotech Private Limited.

The current boards of Lovely Sinharay's companies include Sobhan Sinharay (Pundarik Pharma Private Limited), Pijush Saha (Medikrish Biotech Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available